Great science is necessary. It is not sufficient. Pharma BD teams have three questions for every asset they look at: Where is the patient? Where is the payer story? Where is the deal partner?We answer all three — with the same evidence rigour pharma applies internally, and a success-only fee structure that aligns us with your outcome.
The Three Pillars
Three integrated capabilities. One asset. One outcome — a deal that closes, on terms that reflect what your science is actually worth.
Larger than life
When pharma BD looks at your asset, they should see the same evidence package they themselves would commission. That's what we deliver — without the top-20 consulting fee.
The same systematic reviews, ITCs, and budget-impact models we deliver to top-20 pharma — repackaged for your single asset. The reviewer can't tell the difference.
Problem → Patient → Proof framework. Non-confidential deck. Plain-language value story. Walks into any pharma BD meeting without flinching.
12 years of HEOR / HTA / market access work for global pharma. The same senior team. Just applied to your asset, not someone else's.
Success-based partnering. No retainers. No subscriptions. We invest first; we share success only when your deal closes.
Powered by MarksMan Healthcare — 12 years of HEOR, HTA, market access, RWE and health economic modeling delivered to the world's largest pharma companies. The same senior team. Applied to your single asset.
Send us a non-confidential one-pager. We will tell you — honestly — whether your asset has a partnerable story today, what is missing, and which pharma BD teams should see it first.
Get a free positioning reviewNo upfront fees · Success-only partnering